(Q36328966)

English

Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

1 reference

based on heuristic

inferred from title

author name string

Ronald N Jones

1

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

language of work or name

0 references

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

42 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

S13-24

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001).

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Problems in in vitro determination of antibiotic tolerance in clinical isolates

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Antibiotic tolerance among clinical isolates of bacteria

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Evidence for biliary excretion of vancomycin into stool during intravenous therapy: potential implications for rectal colonization with vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Trends in gram-positive bloodstream organism resistance: a seven-year audit of five glycopeptides and other drugs at a large university hospital.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: five nationwide prevalence studies, 1986 to 2002.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

The sensitivity of staphylococci to antibiotics; a five-year study of sensitivity, usage, and cross resistance in a general hospital.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Emergence of vancomycin resistance in coagulase-negative staphylococci

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Structure, biochemistry and mechanism of action of glycopeptide antibiotics

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotype

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Heterologous expression of the enterococcal vanA operon in methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Vancomycin-resistant Staphylococcus aureus in the clinic: not quite armageddon

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Diffusion of teicoplanin and vancomycin in agar

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Multiple antibiotic resistance in a bacterium with suppressed autolytic system.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Evidence for participation of autolysins in bactericidal action of oxacillin on Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Variation in the susceptibility of strains of Staphylococcus aureus to oxacillin, cephalothin, and gentamicin

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

A new type of penicillin resistance of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Antibiotic Tolerance Among Clinical Isolates of Bacteria

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

The importance of bactericidal drugs: future directions in infectious disease.

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline

1 reference

https://api.crossref.org/works/10.1086%2F491710

21 January 2018

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36328966&oldid=1626709113"